Loading clinical trials...
Loading clinical trials...
Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects w...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
NCT05525858 · Solid Tumor, Advanced Solid Tumor, and more
NCT05076760 · Solid Tumor, Advanced Cancer, and more
NCT06678659 · Unresectable, Locally Advanced, and more
NCT06085716 · Metastatic Cancers, Fatigue
NCT07197671 · Metastatic Cancer
Shun Lu, Ph.D
Shanghai, Shanghai Municipality
Dingzhi Huang, Ph.D
Tianjin, Tianjin Municipality
Wen Li, Ph.D
Hangzhou, Zhejiang
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions